Core Viewpoint - Acadia Healthcare (ACHC) is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ending September 2025, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The upcoming earnings report is scheduled for November 5, and if the results exceed expectations, the stock may rise; conversely, a miss could lead to a decline [2]. - The consensus estimate for quarterly earnings is $0.72 per share, reflecting a year-over-year decrease of 20.9%, while revenues are projected to be $853.31 million, representing a 4.6% increase from the previous year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 1.73% higher, indicating a collective reassessment by analysts [4]. - The Most Accurate Estimate for Acadia Healthcare is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -9.79%, suggesting a bearish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from consensus estimates, with positive readings being more reliable [9][10]. - Acadia Healthcare currently holds a Zacks Rank of 4, which complicates the prediction of an earnings beat [12]. Historical Performance - In the last reported quarter, Acadia Healthcare was expected to post earnings of $0.71 per share but achieved $0.83, resulting in a surprise of +16.90% [13]. - Over the past four quarters, the company has exceeded consensus EPS estimates three times [14]. Conclusion - Acadia Healthcare does not appear to be a strong candidate for an earnings beat, and investors should consider additional factors when making decisions regarding the stock ahead of the earnings release [17].

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Acadia Pharmaceuticals despite higher revenues, with actual results being crucial for stock price movement [1][2]. Financial Expectations - Acadia is expected to report quarterly earnings of $0.14 per share, reflecting a -30% change year-over-year, while revenues are projected at $273.59 million, an increase of 9.3% from the previous year [3]. - The consensus EPS estimate has been revised 1.77% higher in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows that Acadia's Most Accurate Estimate is lower than the consensus estimate, resulting in an Earnings ESP of -19.33%, suggesting bearish sentiment among analysts [12]. - Despite the negative Earnings ESP, Acadia holds a Zacks Rank of 2, complicating predictions of an earnings beat [12]. Historical Performance - In the last reported quarter, Acadia exceeded expectations by delivering earnings of $0.16 per share against an expected $0.14, resulting in a surprise of +14.29% [13]. - Over the past four quarters, Acadia has beaten consensus EPS estimates three times [14]. Industry Context - In the broader Zacks Medical - Biomedical and Genetics industry, Amgen is expected to report earnings of $5 per share, indicating a -10.4% year-over-year change, with revenues projected at $8.94 billion, up 5.2% [18][19]. - Amgen's consensus EPS estimate has been revised down by 0.9% in the last 30 days, leading to an Earnings ESP of -1.25% and a Zacks Rank of 3, making predictions of an earnings beat challenging [19][20].

Core Viewpoint - The market anticipates Alector (ALEC) will report a year-over-year increase in earnings despite lower revenues, with actual results being crucial for stock price movement [1][2]. Company Summary - Alector is expected to report a quarterly loss of $0.42 per share, reflecting a year-over-year change of +2.3% [3]. - Revenues are projected to be $2.63 million, down 82.9% from the same quarter last year [3]. - The consensus EPS estimate has been revised 3.13% lower in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that Alector's Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -5.77% [12]. - Alector currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [12]. Historical Performance - In the last reported quarter, Alector was expected to post a loss of $0.45 per share but actually reported a loss of -$0.30, achieving a surprise of +33.33% [13]. - Over the past four quarters, Alector has beaten consensus EPS estimates four times [14]. Industry Context - Another company in the same industry, AC Immune (ACIU), is expected to report a loss of $0.22 per share, indicating a year-over-year change of -466.7% [18]. - AC Immune's revenues are expected to be $1.52 million, down 94.8% from the previous year [18]. - The consensus EPS estimate for AC Immune has been revised 4.3% higher in the last 30 days, but it also has a negative Earnings ESP of -4.55% [19][20].

Core Viewpoint - Jack Henry (JKHY) is anticipated to report a year-over-year increase in earnings driven by higher revenues for the quarter ended September 2025, with the actual results being crucial for its near-term stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is expected to be released on November 4, with a consensus estimate of quarterly earnings at $1.64 per share, reflecting a year-over-year change of +0.6%. Revenues are projected to be $636.69 million, an increase of 5.9% from the previous year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 0.87%, indicating a reassessment by analysts regarding the company's earnings prospects [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Jack Henry is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -6.42%, suggesting a bearish outlook from analysts [12]. Historical Performance - In the last reported quarter, Jack Henry exceeded the expected earnings of $1.46 per share by delivering $1.75, resulting in a surprise of +19.86%. The company has beaten consensus EPS estimates in the last four quarters [13][14]. Investment Considerations - Despite the potential for an earnings beat, the combination of a negative Earnings ESP and a Zacks Rank of 3 makes it challenging to predict a positive outcome for the upcoming earnings report [12][17].

Company Overview - Ultragenyx (RARE) is expected to report a year-over-year increase in earnings driven by higher revenues for the quarter ended September 2025, with a consensus outlook indicating a quarterly loss of $1.23 per share, reflecting a +12.1% change from the previous year [1][3] - Revenues are anticipated to reach $167.55 million, representing a 20.1% increase compared to the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised 0.43% lower over the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4] - The Most Accurate Estimate for Ultragenyx is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -12.47%, suggesting a bearish outlook from analysts [12] Earnings Surprise History - In the last reported quarter, Ultragenyx was expected to post a loss of $1.27 per share but actually reported a loss of -$1.17, achieving a surprise of +7.87% [13] - Over the past four quarters, the company has beaten consensus EPS estimates two times [14] Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Vertex Pharmaceuticals (VRTX) is expected to report earnings of $4.55 per share for the same quarter, indicating a year-over-year change of +3.9% and revenues of $3.04 billion, up 9.7% from the previous year [18][19] - Vertex has an Earnings ESP of +0.57% and a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [19][20]

Core Viewpoint - uniQure (QURE) is anticipated to report a year-over-year increase in earnings driven by higher revenues in its upcoming quarterly results for September 2025 [1] Financial Expectations - The consensus estimate indicates a quarterly loss of $0.85 per share, reflecting a year-over-year change of +6.6% [3] - Expected revenues are projected at $6.93 million, representing a significant increase of 202.6% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 4.79% higher in the last 30 days, indicating a positive reassessment by analysts [4] - The Most Accurate Estimate for uniQure is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +22.54% [12] Earnings Surprise Potential - A positive Earnings ESP reading suggests a strong likelihood of an earnings beat, especially when combined with a Zacks Rank of 3 [10][12] - Historically, uniQure has beaten consensus EPS estimates three out of the last four quarters, with a notable surprise of +22.47% in the last reported quarter [13][14] Industry Context - In comparison, Axsome Therapeutics (AXSM) is expected to report a loss of $0.85 per share for the same quarter, with revenues projected at $164.05 million, up 56.6% year-over-year [18][19] - Axsome's consensus EPS estimate has been revised 38.2% lower recently, resulting in a negative Earnings ESP of -14.93% [19][20]

Core Viewpoint - The market anticipates a year-over-year decline in Leidos' earnings despite an increase in revenues for the quarter ending September 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Leidos is expected to report earnings of $2.61 per share, reflecting a year-over-year decrease of 10.9%, while revenues are projected to be $4.27 billion, an increase of 1.8% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised 0.26% higher in the last 30 days, indicating a slight positive reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Leidos is lower than the consensus estimate, resulting in an Earnings ESP of -2.30%, suggesting a bearish outlook from analysts [12]. Historical Performance - Leidos has consistently beaten consensus EPS estimates in the past four quarters, with a notable surprise of +22.05% in the last reported quarter [13][14]. Investment Considerations - Despite the historical performance, the current combination of a negative Earnings ESP and a Zacks Rank of 3 makes it challenging to predict an earnings beat for Leidos [12][17].

Core Viewpoint - The market anticipates a year-over-year decline in earnings for LGI Homes due to lower revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - LGI Homes is expected to report quarterly earnings of $1.02 per share, reflecting a year-over-year decrease of 65.4%, with revenues projected at $416.73 million, down 36.1% from the previous year [3]. - The consensus EPS estimate has been revised down by 9.77% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for LGI Homes is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -5.21% [12]. - The stock currently holds a Zacks Rank of 5, indicating a bearish outlook, making it challenging to predict an earnings beat [12]. Historical Performance - In the last reported quarter, LGI Homes exceeded expectations by delivering earnings of $1.36 per share against an expected $1.21, resulting in a surprise of +12.40% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates twice [14]. Conclusion - LGI Homes does not appear to be a strong candidate for an earnings beat, and investors should consider additional factors when evaluating the stock ahead of the earnings release [17].

Core Insights - Wall Street anticipates a year-over-year increase in earnings for Madrigal (MDGL) due to higher revenues, with a focus on how actual results compare to estimates [1][2] - The upcoming earnings report is expected to be released on November 4, and stock movement will depend on whether key numbers exceed or fall short of expectations [2] Financial Expectations - Madrigal is projected to report a quarterly loss of $1.99 per share, reflecting a year-over-year change of +59.6% [3] - Revenues are expected to reach $249.15 million, representing a significant increase of 300.8% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 10.44% higher in the last 30 days, indicating a positive reassessment by analysts [4] - The Most Accurate Estimate for Madrigal is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +27.84% [12] Earnings Surprise Prediction - A positive Earnings ESP reading suggests a likely earnings beat, especially when combined with a Zacks Rank of 2 (Buy) [10][12] - Madrigal has a history of beating consensus EPS estimates, having done so in the last four quarters [14] Industry Context - Another company in the Zacks Medical - Drugs industry, BioCryst Pharmaceuticals (BCRX), is expected to post earnings of $0.07 per share, indicating a year-over-year change of +200% [18] - BioCryst's revenues are projected to be $161.15 million, up 37.6% from the previous year, with an Earnings ESP of +17.12% [19][20]

Core Viewpoint - Oportun Financial Corporation (OPRT) is expected to report a year-over-year increase in earnings despite lower revenues for the quarter ended September 2025, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - The consensus estimate for Oportun Financial's quarterly earnings is $0.26 per share, reflecting a significant year-over-year increase of +1200% [3]. - Revenues are projected to be $238.85 million, which is a decrease of 4.5% compared to the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 3% lower, indicating a reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Oportun Financial is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -13.73%, suggesting a bearish outlook from analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of actual earnings deviating from consensus estimates, with a positive reading being a strong predictor of an earnings beat [9][10]. - Oportun Financial currently holds a Zacks Rank of 3 (Hold), complicating predictions regarding an earnings beat [12]. Historical Performance - In the last reported quarter, Oportun Financial exceeded the expected earnings of $0.22 per share by delivering $0.31, resulting in a surprise of +40.91% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [14]. Industry Comparison - Acadian Asset Management (AAMI), another player in the Zacks Financial - Miscellaneous Services industry, is expected to report earnings of $0.73 per share for the same quarter, representing a year-over-year change of +23.7% [18]. - AAMI's revenues are anticipated to be $145.62 million, up 18.3% from the previous year, with a recent EPS estimate revision of +5.1% [19].